A supplemental biologics license application has been submitted to the FDA for the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
Original Article: FDA Approval Sought for Brentuximab Vedotin in Frontline CD30+ PTCL